Lisa Delfini - 07 Jan 2025 Form 4 Insider Report for Trevi Therapeutics, Inc. (TRVI)

Role
Chief Financial Officer
Signature
/s/ Christopher Galletta, attorney-in-fact
Issuer symbol
TRVI
Transactions as of
07 Jan 2025
Net transactions value
+$3,066
Form type
4
Filing time
10 Jan 2025, 16:14:48 UTC
Previous filing
24 May 2024
Next filing
20 Feb 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TRVI Common Stock Options Exercise $511 +1,000 +1.7% $0.5110 59,660 07 Jan 2025 Direct F1
transaction TRVI Common Stock Options Exercise $2,555 +5,000 +8.4% $0.5110 64,660 08 Jan 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TRVI Stock Option (right to buy) Options Exercise $0 -1,000 -2.1% $0.000000 47,125 07 Jan 2025 Common Stock 1,000 $0.5110 Direct F2
transaction TRVI Stock Option (right to buy) Options Exercise $0 -5,000 -11% $0.000000 42,125 08 Jan 2025 Common Stock 5,000 $0.5110 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 5,381 shares purchased through the Issuer's employee stock purchase plan.
F2 This option was granted on February 11, 2022. The 110,000 shares of common stock underlying the option vested as to 25% of the shares on February 11, 2023 and vest as to the remaining 75% of the shares in equal monthly installments thereafter through February 11, 2026.